QNTM equity, liquidity strengthened as FDA approves Lucid-MS trial
Quantum BioPharma says it strengthens equity and liquidity in Q2 2026 following FDA approval of Lucid-MS for a pivotal Phase 2 clinical trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.